Morning Note

27 August 2024


Corp

Ticker	AZY:ASX
Mining	
Shares in issue (m)	4,768.7
Next results	FY Sept
Price	A\$0.01
Target price	A\$0.04
Upside	300%

Market Cap	A\$57.2m
Net debt/(cash)	-A\$8.1m
Other EV adjustments	A\$0.0m
Enterprise value	A\$49.1m

What's changed?	From	То
Adjusted EPS	-0.0	n/c
Target price	0.04	0.04

Share price performance



%	1M	3M	12M
Actual	9.1	-7.7	-25.0

Company description

Antipa is a mineral exploration company focused on the Paterson Province of Western Australia

Will Dymott

Director of Research wdymott@cavendish.com 0131 220 9109

Sales desk 020 7397 1930

Trading desk 020 7220 0533

* denotes corporate client of Cavendish

Antipa Minerals

Calibre Resource update

Antipa reported a 19% increase to the resource at its 32% held Calibre deposit. The Inferred Mineral Resource estimate (MRE) increased to 111 million tonnes at 0.86 g/t gold-equivalent (0.71 g/t gold, 0.10% copper and 0.44 g/t silver) containing 3.1 million gold-equivalent ounces (2.5 million ounces of gold, 115,000 tonnes of copper and 1.6 million ounces of silver) using a 0.4 g/t gold equivalent cut-off grade.

The Calibre deposit on the Citadel Joint Venture Project (68% Rio Tinto 32%. Antipa) is located 45km east of Rio Tinto's Winu copper-gold-silver development project and Ngapakarra gold-copper deposit.

We maintain our valuation at A\$0.04 (A\$202m) on a sum-of-the-parts basis, underpinned by a solid asset on the development path, all with discovery upside re-rating potential and with potential M&A exits.

- The updated 2024 MRE used a lower cut-off grade of 0.4 g/t Aueq down from 0.5 g/t as used in the May 2021 MRE. This reflects the significant increase in the A\$ gold and copper prices since May 2021. The JORC MRE was prepared by Antipa and reviewed and endorsed by Snowden Optiro.
- A total of 15 drillholes were completed in the Calibre deposit area post the May 2021 MRE, with some drill holes testing shallow resource extensional targets in the southern region of Calibre.
- The scale of the Calibre deposit in conjunction with its off-the-shelf metallurgical characteristics and shallow, predominantly free-digging, post-mineralisation cover, should suit a potential large-scale open pit mining development scenario.
- The Calibre resource extends for approximately 1.4 km and remains open along strike to the south, at depth and potentially across strike. The existing Magnum Inferred Mineral Resource, located just 1.3km from Calibre, provides an additional 340,000 ounces of gold, 57,800 tonnes of copper and 511,000 ounces of silver and remains open at depth and along strike to both the north and south.
- Update of the 2022 Minyari Dome Scoping Study is expected by late-September 2024, and is set to include any potential additional production opportunity that upcoming GEO-01 maiden MRE may provide and to incorporate the sustained significant increase in the Australian dollar gold price.
- Alongside Antipa's own exploration programme for its 100% owned Minyari Dome project, the company continues to work closely with JV partner Rio Tinto, and farm-in partners Newmont and IGO in the execution of the 2024 exploration programmes in the Paterson Province.
- Newmont's decision to divest Telfer and its 70% share of Havieron could act as the catalyst to consolidation in the region. Alongside Rio looking at its options on Winu, there could be a changing of the guard in Western Australia's Paterson Province and consolidation could take place.
- Antipa reported cash at 30 June 2024 of A\$8m (A\$360,000, held on behalf of joint venture and farmin parties). Antipa is funded to complete its near-term exploration programme.

Key estimates		2020A	2021A	2022A	2023A	2024E
Year end:		Jun	Jun	Jun	Jun	Jun
Revenue	A\$m	0.0	0.0	0.0	0.0	0.0
Adj EBITDA	A\$m	-2.4	-4.2	-6.2	-3.3	-1.3
Adj EBIT	A\$m	-2.4	-4.3	-6.4	-3.4	-1.3
Adj PBT	A\$m	-2.4	-4.3	-6.4	-3.3	-1.3
Adj EPS	С	-0.1	-0.1	-0.2	-0.1	-0.0
DPS	С	0.0	0.0	0.0	0.0	0.0

Key valuation metr	ics					
EV/sales	Х	n/m	n/m	n/m	n/m	n/m
EV/EBIT (adj)	X	-20.3	-11.5	-7.7	-14.4	-37.8
P/E (adj)	X	-12.2	-9.2	-6.4	-15.0	-52.2
Dividend yield	%	0.0%	0.0%	0.0%	0.0%	0.0%
Free cash yield	%	-8.3%	-9.5%	-43.5%	-22.2%	-18.0%

Morning Note 27 August 2024

Investment risk

Investing in shares presents risks and opportunities. The past is not necessarily a guide to the future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. The information on future performance in this communication is an illustration and is not a reliable guide to actual future performance.

Non-UK stocks

International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk.

Disclosures

Analyst certification

The Sales Person(s) / Research Analyst(s) responsible for preparing this investment recommendation/report or sections of this report, in whole or in part, hereby certify/ies that, with respect to any and all of the securities or issuers that the Sales Person(s) / Research Analyst(s) cover(s) in this report, the views expressed in this report accurately reflect his/her/their personal views. However, this investment recommendation / report may have been disclosed to the issuer prior to its publication and may have been subject to amendment thereafter. The proprietary models used in production of this investment recommendation are available on request. It is intended that the proprietary models used in this investment recommendation shall be updated when appropriate. In addition, no part of the Sales Person(s) / Research Analyst(s)' compensation was, is, or will be directly or indirectly, related to the specific recommendations or view expressed in this report or summary.

Recommendations definitions

Definition of research recommendations

Expected absolute returns

BUY is an expected return greater than 10%

HOLD is an expected return -10% - +10%

SELL is an expected return less than -10%

UNDER REVIEW: recommendation and/or forecasts are under review pending further clarity as to the company's financial and/or operational position CORP: denotes corporate client of Cavendish Securities plc or Cavendish Capital Markets Limited

For Sales recommendation please refer to https://www.cavendish.com

Distribution of investment recommendations as per 27/08/2024

	Corporate client no.	Corporate client %	Total no.	Total %
Buy	2	1.5%	14	8.9%
Hold	0	0.0%	0	0.0%
Sell	0	0.0%	0	0.0%
Under Review	0	0.0%	0	0.0%
Corp	132	96.4%	144	91.1%

Temporary movements by stocks across the boundaries of these categories due to share price volatility will not necessarily trigger a recommendation change. All recommendations are based on 12-month time horizon unless otherwise stated.

Morning Note 27 August 2024

Recommendation history

Company	Disclosures	Date	Rec	Price	Target price
Antipa Minerals	9	19 October 23	Corp	A\$0.01	A\$0.05
RUA Life Sciences	2,6,8,9,10	1 December 23	Corp	11.8p	25.0p
Shield Therapeutics	2,6,7,8,9,10	14 May 19	Corp	93.9p	188.8p
Source: Cavendish					

A list of all the recommendations produced/issued by the relevant Sales Person / Research Analyst on any financial instrument or issuer disseminated during the preceding 12 months is available upon request free of charge. Please contact the appropriate Cavendish analyst or your Cavendish contact on 020 7220 0500.

Legend

- The Sales / Research Analyst persons closely associated with them and/or persons involved in the preparation of the investment recommendation, has a beneficial interest in the shares of this issuer. This holding(s) was not received or purchased prior to a public offering of such shares
- The Sales / Research Analyst responsible for this investment recommendation may have his/her remuneration linked to investment banking transactions performed by Cavendish.
- 3. A director, officer or employee of Cavendish or a person closely associated to him/her, is an officer, director, or serves as an adviser or board member of the issuer. Where this person is the person responsible for this investment recommendation or a person closely associated with them, this will be indicated.
- 4. As at the date of this investment recommendation / report, Cavendish has a beneficial interest exceeding 5% of the total issued share capital in the issuer.
- 5. As at the date of this investment recommendation / report, the issuer has a beneficial interest exceeding 5% of the total issued share capital of Cavendish.
- 6. Cavendish acts as a market maker or liquidity provider in relation to securities issued by the issuer.
- 7. Cavendish has been the lead manager or co-lead manager in a public offering of the issuer's financial instruments during the previous 12 months.
- 8. Cavendish is party to an agreement with the issuer and has received compensation from the issuer for the provision of investment banking or financial advisory services within the previous 12 months.
- 9. Cavendish is party to an agreement with the issuer relating to the provision of investment recommendations for this issuer and Cavendish may receive remuneration for such service.
- 10. Cavendish acts as a corporate broker to this issuer.
- 11. Cavendish acts as a nominated adviser, financial adviser or as a sponsor to the issuer in the UK.
- 12. As at the date of this investment recommendation, Cavendish has a net short position exceeding 0.5% of the total issued share capital of the issuer
- 13. As at the date of this investment recommendation, Cavendish has a net long position exceeding 0.5% of the total issued share capital of the issuer
- 14. Any other specific disclosures.

Morning Note 27 August 2024

Disclaimer

This communication is NON-INDEPENDENT RESEARCH AND A MARKETING COMMUNICATION under the FCA's Conduct of Business Sourcebook (COBS) and is issued in the UK by Cavendish, the trading name for the business operated by Cavendish Capital Markets Limited and Cavendish Securities plc, both of which are authorised and regulated by the Financial Conduct Authority (FCA) and are members of the London Stock Exchange. Non-independent research has not been prepared in accordance with the legal requirements to promote independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Cavendish considers that this communication constitutes an acceptable minor non-monetary benefit in accordance with chapter 2.3A.19 R (5) (b) or (g) of COBS as appropriate.

This document and any investment to which this document relates is intended for the sole use of the persons to whom it is addressed and is for distribution in the United Kingdom only to 'professional clients' or 'eligible counterparties' within the meaning of chapter 3 of COBS or persons described in Articles 19(5) (Investment professionals) or 49(2) (High net worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) ('FPO') and all other exempt persons under the FPO (all such persons together being referred to as 'Relevant Persons'). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as retail clients under COBS. This document is directed only at Relevant Persons. Other persons should not act or rely on this document or any of its contents. Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. Any investment to which this document relates is available only to such persons, and other classes of person should not rely on this document.

This document has been prepared and issued by Cavendish on the basis of publicly available information, internally developed data and other sources believed to be reliable. Share price performance graphs are sourced from Morningstar, FactSet, Proquote International and Thomson Reuters Datastream. The information contained in this publication was obtained from various sources believed to be reliable, but has not been independently verified by Cavendish. Cavendish does not warrant the completeness or accuracy of such information and does not accept any liability with respect to the accuracy or completeness of such information, except to the extent required by applicable law. Any opinions, projections, forecasts or estimates in this report are those of the author only, who has acted with a high degree of expertise. They reflect only the current views of the author at the date of this report and are subject to change without notice. Cavendish has no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. The analysis, opinions, projections, forecasts and estimates expressed in this report were in no way affected or influenced by the issuer. The author of this publication benefits financially from the overall success of Cavendish.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information may be available on request. This report may not be reproduced for further publication without the prior written permission of Cavendish. This publication is for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction. The investments referred to in this publication may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations that they deem necessary. Any loss or other consequence arising from the use of the material contained in this publication shall be the sole and exclusive responsibility of the investor and Cavendish accepts no liability for any such loss or consequence. In the event of any doubt about any investment, recipients should contact their own investment, legal and/or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in this publication may not be readily liquid investments. Certain transactions, including those involving futures, options, and high yield securities, give rise to substantial risk and are not suitable for all investors should be aware of the additional and special risks associated with securities and investments in emerging markets. Consequently, it may be difficult to sell or realise such investments. The past is not necessarily a guide to future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may caus

Cavendish has written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research business and its production. Cavendish's research analysts and other staff involved in issuing and disseminating research reports operate independently of Cavendish's Corporate Finance business. Information barriers procedures are in place between the Sales and Research Analysts and staff involved in securities trading for the account of Cavendish or its clients to ensure that inside information is handled according to applicable laws and regulations.

Cavendish may be remunerated by a company for writing research on that company, in which case, a specific disclosure will be made in the relevant research report. Each company understands and agrees that the analysis, opinions, projections, forecasts and estimates expressed in such research reports will be honest and unbiased in compliance with Cavendish's Conflicts of Interests and Research Policies and will in no way be influenced by any remuneration received by Cavendish from the company. For further details, please see Cavendish's Conflicts of Interest Policy available on our website at www.cavendish.com.

Cavendish Capital Markets Limited and Cavendish Securities plc are both incorporated and principally operate in England and Wales. Cavendish is not registered as a broker-dealer in the US and relies on the exemption in Rule 15a-6 under the Securities Exchange Act of 1934 when interacting with US persons. For the purposes of this exemption, please note that this publication should not be construed as an invitation, inducement, solicitation or intermediation for the sale, subscription or purchase of any securities or for engaging in any other transaction. Cavendish Capital Markets Limited and its assets are regulated in England and Wales by the FCA (registered number 467766) and Cavendish Securities plc and its assets are regulated in England and Wales by the FCA (registered number 416932). Accordingly, laws, regulations and remedies may differ to those available in the US.

Cavendish is not registered in any Canadian jurisdiction but operates in Canada using the International Dealer and/or Adviser exemption granted by the Ontario Securities Commission, the British Columbia Securities Commission and the AMF in Québec under section 8.18 and/or 8.26 of NI31-103. Laws, regulations and remedies may differ to those available in Canada accordingly.

This document may be distributed to wholesale clients in Australia in reliance on relief pursuant to ASIC Class Order CO 03/1099.

For Entities and Clients in the United States

Cavendish Securities Ltd is not registered as a broker-dealer with the US Securities and Exchange Commission, and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Cavendish is not a member of the Financial Industry Regulatory Authority. It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest.

This research report is only being offered to US Institutional Investors via our US chaperoning broker Auerbach Grayson and Company and is not available to, and should not be used by, any US person or entity that is not a US Institutional Investor. Cavendish cannot and will not accept orders for the securities covered in this research report placed by any person or entity in the United States. Orders should be placed with our correspondent, Auerbach Grayson & Company at 212-557-4444.

A Major US Institutional Investor who may receive and use this report must have assets under management of more than US\$100,000,000 and is either an investment company registered with the SEC under the US Investment Company Act of 1940, a US bank or savings and loan association, business development company, small business investment company, employee benefit plan as defined in SEC Regulation D, a private business development company as defined in SEC Regulation D, an organisation described in US Internal Revenue Code Section 501(c)(3) and SEC Regulation D, a trust as defined in SEC Regulation D, or an SEC registered investment adviser or any other manager of a pooled investment vehicle.

www.cavendish.com